First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumorsRom S. Leidner, John A. Thompson|Journal for ImmunoTherapy of Cancer|2023Cited by 23